drugset / Trial / NCT01416324
First Time in Human Study Using GSK2330672
RandomizedCrossoverSingle-blindBasic science
Summary
The purpose of this study is to look at the safety and tolerability of increasing single doses of GSK2330672 in healthy volunteers.
Timeline
- Start
- 2011-06-15
- Primary completion
- 2011-09-09
- Completion
- 2011-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linerixibat | Small molecule | 0.1 mg | Oral |
| Subject | Linerixibat | Small molecule | 0.3 mg | Oral |
| Subject | Linerixibat | Small molecule | 1 mg | Oral |
| Subject | Linerixibat | Small molecule | 3 mg | Oral |
| Subject | Linerixibat | Small molecule | 10 mg | Oral |
| Subject | Linerixibat | Small molecule | 30 mg | Oral |
| Subject | Linerixibat | Small molecule | 60 mg | Oral |